Barclays Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock

BioCryst Pharmaceuticals (NASDAQ:BCRX) had its price target raised by Barclays from $7.00 to $8.00 in a report published on Tuesday,Benzinga reports. The brokerage currently has an equal weight rating on the biotechnology company’s stock.

A number of other research firms also recently commented on BCRX. StockNews.com upgraded BioCryst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 6th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, August 6th. JMP Securities lifted their price objective on shares of BioCryst Pharmaceuticals from $15.00 to $16.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 6th. Finally, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a research report on Tuesday, August 6th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $14.67.

BioCryst Pharmaceuticals Stock Performance

BioCryst Pharmaceuticals stock opened at $7.78 on Tuesday. BioCryst Pharmaceuticals has a 1 year low of $4.03 and a 1 year high of $8.88. The firm’s 50 day moving average price is $7.76 and its two-hundred day moving average price is $7.00. The firm has a market cap of $1.61 billion, a price-to-earnings ratio of -12.75 and a beta of 1.89.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.07). The firm had revenue of $117.10 million for the quarter, compared to analyst estimates of $113.99 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. The firm’s revenue was up 35.1% compared to the same quarter last year. As a group, equities analysts predict that BioCryst Pharmaceuticals will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC increased its stake in BioCryst Pharmaceuticals by 200.0% during the second quarter. CWM LLC now owns 5,658 shares of the biotechnology company’s stock valued at $35,000 after acquiring an additional 3,772 shares during the period. Signaturefd LLC boosted its position in shares of BioCryst Pharmaceuticals by 560.5% during the 2nd quarter. Signaturefd LLC now owns 6,598 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 5,599 shares in the last quarter. Seven Eight Capital LP acquired a new stake in BioCryst Pharmaceuticals during the first quarter valued at approximately $57,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares in the last quarter. Finally, Natixis grew its position in BioCryst Pharmaceuticals by 400.6% in the first quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares during the period. Institutional investors and hedge funds own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.